OncologyPipeline is your comprehensive solution for oncology intelligence and offers you a unique and competitive edge.

Our offering is designed to save you time and maximize value by identifying key opportunities and mitigating risks. Our senior team members worked in leadership positions at companies such as Genentech/Roche, GSK, and Novartis and we bring unparalleled expertise to the table. .

Our Key Services:
  • OncologyPipeline Database: the industry benchmark for comprehensive oncology insights, including competitors, trials, results, approval timelines, and more; all supported by our top-rated "Ask the Analyst" service
  • OncologyPipeline Reports: off-the-shelve or 100% customized reports by our oncology experts to analyse specific tumors, targets, modalities, companies
  • OncologyPipeline Consulting: expert consulting from our senior team members on BD&L Opportunities, Clinical Development Plans, Portfolio Strategy Recommendations, or Financial Forecasts, among others
  • OncologyPipeline Congress Coverage: our team members on site can provide tailor-made coverage from key congresses

Please edit the text below and hit the send button.

I am interested in
OncologyPipeline Demo
Tailor-made Reports
Consulting Services
Congress Coverage
Newsletter Subscription

Name Surname Email Company Job Title

We look forward to discussing how we can support you!

Best regards

Andreas Abt, MD
CEO OncologyPipeline
Our senior team members are:
Andreas Abt
Andreas Abt, MD
Andreas is the founder and CEO of OncologyPipeline. Before OncologyPipeline he worked 20 years at Roche where he held leadership positions of increasing responsibility.
He led a large cross functional team at Roche’s HQ in Switzerland responsible for the late-stage development and commercialization of Rituximab. His team conducted several pIII trials that led to approvals in Europe and later in the United States. Andreas was then Commercial Director for Oncology in HQ and General Manager for Roche in Belgium and in Spain where he was in charge of one of the largest affiliates with over 1.000 employees. Andreas is a Medical Doctor (Basel University, Switzerland) and holds an MBA from INSEAD (Fontainebleau, France).
Madeleine Armstrong
Madeleine Armstrong, BSc
Madeleine has over 16 years’ experience writing about the biopharma and medtech industries. She joined ApexOnco in 2023, after eight years at Evaluate Vantage, most recently as News Editor.
Before that, she was Deputy Editor of Clinica, a medical device publication, and has also worked for Scrip as a reporter. Madeleine also has experience moderating industry events and hosting webinars. She has a degree in Neuroscience, and has built a reputation as a leading voice in gene therapy.
Patricia Baltanas
Patricia Baltanas, BEng
Patricia is the head of the business analytics team at OncologyPipeline. She previously worked at GSK for over 10 years where she held different managing positions in business intelligence and commercial operations.
She has expertise in pipeline and commercial analysis, forecasting and market research across multiple stages of product development. Patricia holds an MBA in pharmaceutical industry and a bachelor's degree in biochemical engineering from University College London.
Dimitri Papadopoulos
Dimitri Papadopoulos, PhD
Dimitri is a molecular geneticist by training and joins OncologyPipeline as a consultant in 2024, after more than 25 years of experience in the pharmaceutical industry.
His expertise is in early commercial and portfolio strategy, where he shaped positioning and strategy for numerous projects between target validation and full development, and participated in several licensing decisions in his latest industry role. Before that, he held various commercial and medical affairs leadership positions in countries on two continents and at global level at Roche and Novartis. He realised various consulting projects in the commercial space for startup companies as well as for launch preparation in Europe.
Jacob Plieth
Jacob Plieth, BSc
Jacob has 27 years' experience of writing about healthcare, and joined ApexOnco in 2023 after 11 years’ reporting on biopharmaceuticals for Evaluate Vantage.
Before that he spent five years as an equity research analyst at Edison Investment Research, and has also worked at Dow Jones/Wall Street Journal and Scrip, where he was news editor. Jacob is a biochemist by training. He is a well-known presence on Biotech TV and Biotech Hangout, and has spoken about pharmaceuticals on the BBC World Service and News 24, as well as chairing industry discussions at various meetings.